Adaptive changes in M1 muscarinic receptors localized to specific rostral brain regions during and after morphine

Related Experiment Video

Updated: Oct 15, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

L C Zhang1, J J Buccafusco

  • 1Alzheimer's Research Center, Department of Pharmacology and Toxicology, Medical College of Georgia, GA 30912-2300, Augusta, USA.

Neuropharmacology
|July 8, 2000
PubMed

Insights

Morphine withdrawal significantly alters M1 muscarinic receptor mRNA in rat brains, particularly in the hippocampus, suggesting long-term changes in cholinergic activity and memory function.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Opioid dependence and withdrawal involve complex neuroadaptations.
  • Muscarinic acetylcholine receptors (mAChRs), particularly the M1 subtype, play crucial roles in cognitive functions.
  • Understanding receptor changes during withdrawal is vital for developing targeted therapies.

Purpose of the Study:

  • To investigate the regional changes in M1 muscarinic receptor expression during morphine withdrawal in rats.
  • To compare direct receptor measurement with mRNA level quantification.
  • To assess the effect of a cholinesterase inhibitor (DFP) on these adaptive changes.

Main Methods:

  • Morphine-dependent rats were subjected to abrupt withdrawal.
  • M1 muscarinic receptor mRNA levels were quantified using RT-PCR.
  • Direct receptor binding was assessed using autoradiography with [(3)H]pirenzepine.
  • Diisopropylflurophophate (DFP) was administered during morphine infusion.

Main Results:

  • Morphine withdrawal led to a significant decrease in hippocampal M1 mRNA levels (57%), persisting even after symptom resolution.
  • Frontal cortex showed an initial increase in M1 mRNA during infusion, followed by a decrease (33.4%) during withdrawal.
  • DFP administration attenuated the withdrawal-induced decrease in hippocampal M1 mRNA.

Conclusions:

  • Morphine withdrawal induces significant, long-lasting alterations in M1 muscarinic receptor mRNA expression in specific brain regions.
  • The hippocampus appears particularly vulnerable, with reduced M1 mRNA potentially impacting memory.
  • These findings highlight the neuroadaptive changes in cholinergic systems during opioid withdrawal.

More Related Videos

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats04:11

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats

Published on: November 6, 2018

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...